- Agilent Technologies (A, Financial) appoints Pascal Soriot and Judy Gawlik Brown to Board of Directors.
- Soriot and Brown bring extensive expertise from global pharmaceutical and financial sectors.
- Heidi Kunz retires from Agilent's Board after more than 20 years of service.
Agilent Technologies Inc. (A), a leading firm in analytical and clinical laboratory technologies, has announced the election of Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, to its Board of Directors. The appointments are effective from May 21, 2025, as part of Agilent's strategic move to support its next phase of growth.
Pascal Soriot, known for transforming AstraZeneca into a global leader in science-driven innovation, brings decades of experience in pharmaceutical industry leadership. His past roles include CEO of Genentech and Chief Operating Officer of Roche’s pharmaceutical division. Similarly, Judy Gawlik Brown is highly regarded for her strategic and financial expertise within the life-sciences sector, having held significant roles at companies such as Amgen and Perrigo Company.
Agilent’s CEO, Padraig McDonnell, expressed confidence in the new appointments, noting Soriot's global pharmaceutical-industry leadership experience as well as Brown's financial expertise as crucial assets to Agilent's future endeavors. Chairman of the Agilent Board, Koh Boon Hwee, highlighted that Soriot and Brown’s skills and professionalism would greatly benefit the company and its shareholders.
Additionally, Agilent announced the retirement of Heidi Kunz from the Board of Directors, effective the same day, marking the end of her more than 20 years of service. Kunz had played a foundational role since Agilent's inception, contributing significantly to the company's growth and evolution.
Agilent Technologies (A, Financial), headquartered in Santa Clara, California, reported a revenue of $6.51 billion for the fiscal year 2024 and employs approximately 18,000 people globally. The company continues to be a major player in the Diagnostics & Research industry, with a strong institutional ownership of 91.65%.
